Core Viewpoint - The AI Fund Yinhua Medical Health Mixed A (018364) reported a profit of 772,600 yuan for Q2 2025, with a weighted average profit per fund share of 0.0195 yuan, indicating a net value growth rate of 2.25% during the reporting period [3]. Fund Performance - As of July 17, the fund's unit net value was 0.923 yuan, with a three-month net value growth rate of 16.98%, ranking 104 out of 138 comparable funds [4]. - The fund's six-month net value growth rate was 10.74%, ranking 130 out of 138, and the one-year growth rate was 11.90%, ranking 120 out of 133 [4]. Fund Management Insights - The fund management believes that the risks associated with the significant decline in profitability in the pharmaceutical industry have been largely eliminated due to gradual policy optimization and the expansion of commercial insurance [3]. - The management highlights that technological innovation is the core driving force for the pharmaceutical industry's development, with a focus on innovative drugs and AI medical applications [3]. Investment Strategy - The fund's long-term investment strategy is concentrated on AI drug development and AI medical applications, which are expected to enhance cost efficiency and innovation within the pharmaceutical sector [3]. Fund Metrics - As of June 27, the fund's Sharpe ratio since inception was -0.0151 [8]. - The maximum drawdown since inception was 34.55%, with the largest quarterly drawdown occurring in Q1 2024 at 27.52% [11]. - The average stock position since inception was 88.71%, compared to the industry average of 86.9% [14]. The fund reached a peak stock position of 93.17% by the end of 2024 [14]. Fund Size and Holdings - As of the end of Q2 2025, the fund's size was 35.6523 million yuan [15]. - The top ten holdings of the fund included companies such as Crystal Technology Holdings, Yimaitong, and JD Health, among others [18].
银华医疗健康混合A：2025年第二季度利润77.26万元 净值增长率2.25%
Sou Hu Cai Jing·2025-07-18 08:22